Clinical Gene Networks (CGN) is the first Swedish Bio-IT company currently situated at the Karolinska Science Park in Stockholm. The company was founded in 2003 by Johan Bj√∂rkegren based on the idea that biological and pathological molecular events are best represented by regulatory gene networks that can be inferred directly from the clinical setting. In 2005, Vinnova (the Swedish Governmental Agency for Innovation Systems) awarded CGN for being one of the ten most promising Swedish start-ups all categories. During 2005 to 2011, CGN has been part of several integrated projects as a SME and Vinnova projects helping CGN to further finance and build the AtheroCode. In 2012 CGN has raised capital from Estonian VC and has appointed Kaidi Ruusalepp, the former CEO of NASDAQ OMX Tallinn, the CEO of CGN. With this we have strengthened both scientific and business know-how in company. 

In collaboration with its academic partners, CGN has now identified many hundred tissue and cross-tissue networks underlying carotid and coronary artery disease (CAD), the main causes of myocardial infarction (MI) and stroke.  With detailed network-maps acting to cause CAD, the goal is to provide pharmaceutical companies with better defined drug candidates (i.e. small molecular, chemical compounds and/or antibodies). In addition, we define sets of biomarkers in blood that are capable of predicting CAD before causing life-threatening clinical manifestations, like MI and stroke. CGN will also proposer from the concept that disease network status in any given individual will serve as the foundation on which personalized medicine eventually can evolve. Unlike isolated genes, the individual disease network status is the tool needed to tailor type and dosage of individual therapy regimes and to monitor the individual response to this regime over time. 

Since its start, CGN has used man hours corresponding to 2-4 full time employees over the years mainly with funds from Swedish governmental agencies and from the European commission as a SME (Small&Middle Size Enterprises) of integrated projects in the 6th and 7th EU frameworks.